№ lp_1_2_10726
File format: docx
Character count: 6920
File size: 128 KB
The document provides an overview of the role of physical therapy in the management of glioblastoma multiforme (GBM) and presents recent research on treatment developments and challenges in GBM care.
Year:
2023
Region / City:
United States
Topic:
Glioblastoma Multiforme, Physical Therapy, Research Updates
Document Type:
Fact Sheet
Organization:
ANPT
Author:
Willie Ching, PT, DPT, Board Certified Specialist in Neurologic Physical Therapy
Target Audience:
Healthcare professionals, patients with GBM, caregivers
Period of Action:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Author:
Willie Ching, PT, DPT, Board Certified Specialist in Neurologic Physical Therapy
Contextual Description:
A fact sheet referencing various studies and research articles on Glioblastoma Multiforme, including treatment options and clinical trials.
Author:
Willie Ching, PT, DPT, Board Certified Specialist in Neurologic Physical Therapy
Organization:
American Physical Therapy Association (APTA) – Neurology Section
Document Type:
Fact Sheet
Medical Condition:
Glioblastoma Multiforme (GBM)
Target Audience:
Healthcare professionals, patients, caregivers
Diagnostic Methods:
MRI, biopsy
Treatment Methods:
Surgery, radiation therapy, chemotherapy (Temozolomide), tumor-treating fields (TTFields)
Epidemiology:
Incidence 2–3 per 100,000 adults per year, median age 64, higher prevalence in men and Caucasians
Survival Rates:
26–33% at 2 years, 4–5% at 5 years
Risk Factors:
Ionizing radiation, certain chemical exposures, genetic syndromes (neurofibromatosis, tuberous sclerosis, Li-Fraumeni, retinoblastoma, Turcot syndrome)
Contact:
ANPT, Phone 952.646.2038, [email protected]
Note:
, www.neuropt.org
Document Type:
Supplementary research methods
Research Field:
Tumor immunology
Disease Focus:
Glioblastoma multiforme
Molecular Focus:
ICOSLG-mediated signaling and IL-10–producing regulatory T cells
Experimental Models:
Human glioma stem cells, murine RasR2 glioma-initiating cells, CD4+ naïve T cells
Biological Materials:
Patient-derived neurospheres, peripheral blood mononuclear cells
Techniques:
Flow cytometry, immunofluorescence staining, luciferase reporter assay, siRNA transfection, hypoxia induction, cytometry by time-of-flight (CyTOF)
Cell Culture Conditions:
Defined DMEM/F12 medium with B27, heparin, EGF, and bFGF
Key Molecular Targets:
ICOSLG, NF-κB, Foxp3, STAT5, PD-L1, HLA molecules
Reagents and Antibodies:
Commercial reagents and antibodies from multiple biotechnology suppliers
Associated Experiments:
Analysis of ICOSLG expression, NF-κB promoter activity, tumor-conditioned medium effects on T cells
Source Material:
Surgical glioma specimens and established experimental cell lines
Note:
Year
Author:
Willie Ching, PT, DPT, Board Certified Specialist in Neurologic Physical Therapy
Contextual Description:
A fact sheet referencing various studies and research articles on Glioblastoma Multiforme, including treatment options and clinical trials.
Author:
Willie Ching, PT, DPT, Board Certified Specialist in Neurologic Physical Therapy
Organization:
American Physical Therapy Association (APTA) – Neurology Section
Document Type:
Fact Sheet
Medical Condition:
Glioblastoma Multiforme (GBM)
Target Audience:
Healthcare professionals, patients, caregivers
Diagnostic Methods:
MRI, biopsy
Treatment Methods:
Surgery, radiation therapy, chemotherapy (Temozolomide), tumor-treating fields (TTFields)
Epidemiology:
Incidence 2–3 per 100,000 adults per year, median age 64, higher prevalence in men and Caucasians
Survival Rates:
26–33% at 2 years, 4–5% at 5 years
Risk Factors:
Ionizing radiation, certain chemical exposures, genetic syndromes (neurofibromatosis, tuberous sclerosis, Li-Fraumeni, retinoblastoma, Turcot syndrome)
Contact:
ANPT, Phone 952.646.2038, [email protected]
Note:
, www.neuropt.org
Year:
2021
Region / City:
Rome, Italy
Field:
Cancer Research
Document Type:
Article
Organization / Institution:
Sapienza University of Rome, University of Milan, Consiglio Nazionale delle Ricerche (CNR), University of Trento, University of Ferrara
Authors:
Guerriero, Claudia; Manfredelli, Marianna; Matera, Carlo; Iuzzolino, Angela; Conti, Luciano; Dallanoce, Clelia; De Amici, Marco; Trisciuoglio, Daniela; Tata, Ada Maria
Target Audience:
Researchers in Cancer Biology
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Keywords:
glioblastoma; cancer stem cells; M2 muscarinic receptor; orthosteric and dualsteric muscarinic agonism; autophagy; apoptosis; mTORC1
Funding:
Ateneo Sapienza Funds
References:
Aoki H, 2008, Autophagy, V4, P467, DOI 10.4161/auto.5668
Context:
Scientific article exploring the role of M2 muscarinic receptor stimulation in inducing autophagy and apoptosis in glioblastoma cancer stem cells, and the differential effects of orthosteric and dualsteric agonists.
Document Type:
Supplementary research methods
Research Field:
Tumor immunology
Disease Focus:
Glioblastoma multiforme
Molecular Focus:
ICOSLG-mediated signaling and IL-10–producing regulatory T cells
Experimental Models:
Human glioma stem cells, murine RasR2 glioma-initiating cells, CD4+ naïve T cells
Biological Materials:
Patient-derived neurospheres, peripheral blood mononuclear cells
Techniques:
Flow cytometry, immunofluorescence staining, luciferase reporter assay, siRNA transfection, hypoxia induction, cytometry by time-of-flight (CyTOF)
Cell Culture Conditions:
Defined DMEM/F12 medium with B27, heparin, EGF, and bFGF
Key Molecular Targets:
ICOSLG, NF-κB, Foxp3, STAT5, PD-L1, HLA molecules
Reagents and Antibodies:
Commercial reagents and antibodies from multiple biotechnology suppliers
Associated Experiments:
Analysis of ICOSLG expression, NF-κB promoter activity, tumor-conditioned medium effects on T cells
Source Material:
Surgical glioma specimens and established experimental cell lines
Document Type:
Supplementary Methods
Scientific Field:
Molecular Biology; Cancer Biology; Nanomedicine
Research Focus:
Exosome-mediated delivery of metformin and siRNA in glioblastoma cells
Biological Materials:
Primary GBM cells (N9, TBD0220); murine brain endothelial cells (bEnd.3); GBM cell lines (GL261, CT2A); neuronal cells (HT22); astrocyte cells (C8-DIA)
Key Molecules:
PTRF protein; cPLA2; metformin; siRNA (siPTRF, chol-sicPLA2)
Experimental Techniques:
Cell culture; lentiviral transfection; siRNA transfection; ultracentrifugation; western blot analysis; confocal laser scanning microscopy; flow cytometry; FRAP membrane fluidity assay; electroporation; nanoparticle tracking analysis; transmission electron microscopy; dynamic light scattering; high-performance liquid chromatography; Seahorse extracellular flux analysis
Biological Structures Studied:
Blood-derived exosomes
Analytical Software:
ImageJ
Laboratory Equipment:
CLSM (FV1200 Olympus); NanoSight NS300; JEM-2100F TEM; Bio-Rad Gene Pulser Xcell Electroporation System; Seahorse XF24 Analyzer
Chemical Reagents:
fetal bovine serum; metformin; DiI dye; Cy5 dye; oligomycin; FCCP; rotenone; antimycin A
Purpose of Experiments:
Investigation of cellular uptake, membrane fluidity, mitochondrial function, and delivery efficiency of engineered exosomes in GBM cells
Geographical Reference of Reagents:
Shanghai, China; Suzhou, China; Beijing, China; USA
Year:
2017
Institution:
The University of Texas MD Anderson Cancer Center
Region / City:
Houston, TX, USA
Document type:
Supplementary materials
Subject:
Glioblastoma stem cells, REST and DRD2 pathways
Methods:
Cell culture, immunofluorescence, RNA preparation, qRT-PCR, chromatin immunoprecipitation, genome-wide expression analysis, Western blot, ChIP-Seq
Target audience:
Researchers in molecular biology and oncology
Approval:
Institutional review board approved
Experimental models:
HR-GSC1, HR-GSC2, LR-GSC cell lines
Key reagents:
Lentiviral vectors, antibodies, Trizol, microarrays
Analysis software:
Agilent GeneSpring GX, Ingenuity Pathway Analysis
Supplementary content:
Materials and methods, figure legends
Year:
2023
Region / City:
Florida
Topic:
Faculty Senate Bylaws, Campus Safety, AI Implementation, State Funding Program Proposals
Document Type:
Meeting Minutes
Organization / Institution:
Faculty Senate
Author:
Tim Bishop, Dr. Bilsky, Dr. Shawn Moore, Dr. Elijah Pritchett, Kelsea Cid, Terri Taggart
Target Audience:
Full-time Faculty
Action Period:
October 2023
Approval Date:
October 2023
Amendments Date:
October 2023
Year:
2025
Region / City:
Letterkenny
Topic:
Juvenile Justice, Criminal Law
Document Type:
Lecture
Organization / Institution:
Atlantic Technological University
Author:
Ms. Justice Aileen Donnelly
Target Audience:
Legal professionals, academics, students
Period of Effect:
N/A
Approval Date:
29 April 2025
Date of Changes:
N/A
Note:
Year
Version:
V6.2.02
Release Date:
January 2026
Previous Versions:
V6.1.02 January 2025, V6.0.04 November 2024, V6.0.03 January 2024
Software:
HSPiP
Content Type:
Release Notes / Software Update
Key Features:
Sphere Explorer, Y-MB updates, QSAR improvements, Polymer SMILES updates, RDKit integration
Bug Fixes:
Decimal place inconsistencies, 3D wire-frame display, HSP calculation corrections
Datasets Included:
PolyOmics dataset, solubility data
Developer / Contributor:
Prof Yoshida (PolyOmics dataset permission)
Platform:
Windows (assumed from context)
Year:
2025
Region / City:
Global
Topic:
Research, Cochrane Reviews
Document type:
Checklist
Organization / Institution:
Cochrane
Author:
Cochrane Central Editorial Service
Target audience:
Authors submitting Cochrane reviews
Period of validity:
Not specified
Approval date:
22 May 2025
Date of amendments:
Not specified
Year of issue:
2012–2019
Organization:
Joint Rig Committee
Document type:
Code of Practice / Scope of Work / Certificate Requirements
Region:
International offshore operations
Target audience:
Marine Warranty Surveyors, underwriters, project assurance teams
Version:
1–3
Date of issue:
27 January 2012, 20 December 2016, 03 September 2019
Changes:
Original; Update to COP & SOW and introduction of JR2012A; Update to COP & SOW
Approval requirements:
Marine Warranty Surveyor certification, compliance with COP and SOW
Operations covered:
Rig location, rig move, marine operations, equipment suitability
Confidentiality and conflict of interest considerations:
Included
Year:
2024
Region / City:
Milton
Topic:
Electricity distribution rates, rate adjustments, and regulatory filings
Document Type:
Regulatory Filing
Organization:
Milton Hydro Inc.
Author:
Milton Hydro Inc.
Target Audience:
Ontario Energy Board (OEB) staff, regulatory bodies
Period of validity:
Q4 2024
Approval Date:
October 1, 2024
Date of changes:
None
Year:
2024
Region:
Massachusetts, USA
Document Type:
Transmittal Letter / Provider Manual Update
Issuing Organization:
Commonwealth of Massachusetts, Executive Office of Health and Human Services, Office of Medicaid
Author:
Monica Sawhney, Chief of Provider, Family, and Safety Net Programs
Target Audience:
Acute Outpatient Hospitals Participating in MassHealth
Effective Date:
July 1, 2024
Content Scope:
Revisions to drug codes, HCPCS codes, CPT codes, billing instructions, and procedural guidelines
Referenced Resources:
MassHealth Drug List, Centers for Medicare & Medicaid Services HCPCS website
Distribution:
MassHealth website and email alerts
Year:
2024
Region / City:
Scotland
Topic:
National Care Service, healthcare, social care
Document Type:
Briefing
Organization / Institution:
The Health and Social Care Alliance Scotland (the ALLIANCE)
Author:
Not specified
Target Audience:
Not specified
Period of Validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2023
Region / City:
England
Topic:
Technical Security Policy for Schools
Document Type:
Template
Organization / Institution:
SWGfL Online Safety Group
Author:
SWGfL Online Safety Group
Target Audience:
Governors, Senior Leaders, IT Service Providers, Designated Safeguarding Leads (DSLs)
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
September 2023
Year:
2023
Region / city:
United States
Topic:
MDS 2023 Updates, Training Plan Design
Document Type:
Guidelines
Organization / Institution:
Centers for Medicare & Medicaid Services (CMS)
Author:
Centers for Medicare & Medicaid Services (CMS)
Target Audience:
Healthcare facilities, staff involved in resident care
Effective Period:
Ongoing
Approval Date:
Not specified
Revision Date:
Not specified